The RegMedEXPO has been developed during the H2020 Project n-TRACK. Following the end of the project in 2021, the RegMedEXPO Community has been open to the partners outside the n-TRACK Project.
A current H2020 project, TriAnkle (3D printing of personalized implants for tendons and cartilages in ankle injuries), is now part of the RegMedEXPO Community, where their activities will be also showcased.
TriAnkle – 3D printing of personalized implants for tendons and cartilages in ankle injuries
The TriAnkle is an innovative medical application that aims to improve the junctions and cartilages (and therefore, the overall movement) of the ankle by introducing a tailored, 3D bio-printed collagen-and-gelatin based structure in the affected area. This is a 48-month project that started in January 2021. It has received funding from the European Union’s Horizon 2020 research and innovation framework programme under the Grant Agreement #952981.
TriAnkle is a team of 12 leading international organisations covering the complete spectrum from advanced research to the market. Viscofan BioEngineering and Cellink are the industry partners, working with various associates, such as FC Barcelona Innovation Hub, Osteoarthritis Foundation International (OAFI), Fraunhofer IGB, University of Stuttgart, Universidad del País Vasco (UPV), Eindhoven University of Technology, Leitat Technological Center, Cambridge Nanomaterials Technology (CNT), Gradocell and Fundacio Clinic per a la Recerca Biomedica.
n-TRACK – Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration
The nTRACKawas a 4-year EU Horizon 2020 project that started in October 2017 (www.n-track.eu) and finished in September 2021. This project had the aim to develop a safe and highly sensitive multimodal nano imaging agent enabling non-invasive, quantitative and longitudinal stem cell tracking and whole-body bio distribution. nTRACK also provides information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labelling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal was to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and bio distribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.
The n-TRACK Project Partners are LEITAT, Asphalion, BIOEMTECH, Cambridge Nanomaterials Technology Ltd, MJR PharmJet GmbH, RIVM, Unimedizin Mainz (UMC), Vivotecnia Research S.L, Vall d’Hebron Research Institute (VHIR), Bar Ilan University, Pluristem Therapeutics and National Center for Scientific Research “Demokritos”.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 761031